List of Excipients in Branded Drug ALEVE ARTHRITIS PAIN GEL

« Back to Dashboard

Generic Drugs Containing ALEVE ARTHRITIS PAIN GEL

Company	Ingredient	NDC	Excipient
Bayer HealthCare LLC	diclofenac sodium	0280-0039	AMMONIA
Bayer HealthCare LLC	diclofenac sodium	0280-0039	CARBOMER HOMOPOLYMER TYPE C
Bayer HealthCare LLC	diclofenac sodium	0280-0039	COCOYL CAPRYLOCAPRATE

What are the Most Frequently-Used Excipients in ALEVE ARTHRITIS PAIN GEL?

# Of NDCs	Excipient
1	AMMONIA
1	CARBOMER HOMOPOLYMER TYPE C
1	COCOYL CAPRYLOCAPRATE

Aleve Arthritis Pain Gel Excipient Strategy and Commercial Opportunities

Last updated: November 4, 2026

Aleve Arthritis Pain Gel is a topical diclofenac product positioned for over-the-counter arthritis pain relief. Its commercial value depends on more than diclofenac sodium concentration. The formulation must balance skin penetration, low irritation, spreadability, drying time, cosmetic acceptability, preservative control, package compatibility, and manufacturing cost. The strongest opportunities are differentiated generic and private-label gels, fragrance-free sensitive-skin products, higher-convenience packaging, and region-specific formulations that comply with local OTC rules.

What is Aleve Arthritis Pain Gel?

Aleve Arthritis Pain Gel is an OTC topical nonsteroidal anti-inflammatory drug product containing diclofenac sodium at 1% in the U.S. presentation. Diclofenac reduces prostaglandin synthesis through cyclooxygenase inhibition. The topical route is intended to provide local drug delivery with lower systemic exposure than oral NSAID administration, although systemic absorption and NSAID warnings remain relevant.[1]

Attribute	Aleve Arthritis Pain Gel
Brand	Aleve
Active ingredient	Diclofenac sodium
Strength	1% in the U.S. product presentation
Dosage form	Topical gel
Primary use	Temporary relief of arthritis pain
Regulatory category	OTC drug product
Primary commercial comparator	Voltaren Arthritis Pain Gel and generic diclofenac sodium topical gel
Typical package	Multi-dose tube or pump presentation, depending on market
Principal formulation challenge	Delivering diclofenac through the skin without excessive greasiness, irritation, or residue

Product composition should be confirmed against the current package insert and DailyMed record because excipient inventories and labeling can vary by country, manufacturing site, and package configuration.[1,2]

What excipients are used in Aleve Arthritis Pain Gel?

Public labeling for diclofenac sodium topical gel products identifies a solvent, penetration-supporting excipients, gelling polymer, emulsifying or solubilizing agents, pH-adjusting components, and water. A representative U.S. formulation includes the following excipient classes:[1,2]

Excipient or excipient class	Formulation function	Commercial importance
Purified water	Continuous phase and primary vehicle	Low cost; requires microbial control
Isopropyl alcohol	Solvent and volatile drying agent	Improves drying; can increase stinging and flammability controls
Propylene glycol	Cosolvent, humectant, penetration-supporting agent	Supports diclofenac solubilization and skin delivery
Carbomer homopolymer	Gel-forming polymer	Controls viscosity, application feel, and suspension stability
Diethylamine	Neutralizing agent and diclofenac salt-forming component	Affects pH, solubility, and skin tolerability
Mineral oil	Emollient and sensory modifier	Reduces skin dryness but can increase residue
Polyoxyl 20 cetostearyl ether	Surfactant or emulsifier	Supports phase stability and drug distribution
Cocoyl caprylocaprate	Emollient and spreading agent	Improves glide and cosmetic feel
Benzyl alcohol, where present	Preservative and solvent	May create sensitization concerns in sensitive-skin segments

The excipient system is not interchangeable on a one-for-one basis. Changing the carbomer grade, neutralizer, alcohol content, or surfactant can alter diclofenac solubility, viscosity, release rate, skin permeation, preservative effectiveness, and tube evacuation. A formulation that matches the active concentration but changes the vehicle materially may require comparative performance, stability, and regulatory justification.

How does the excipient system support diclofenac delivery?

Diclofenac sodium is a weakly acidic, ionizable drug. The formulation must keep enough drug dissolved or finely distributed in the vehicle while creating a concentration gradient across the stratum corneum. The solvent and cosolvent system controls thermodynamic activity, while the gel polymer controls residence time and application properties.

Solvent and cosolvent balance

Isopropyl alcohol can improve drying and produce a non-greasy feel. Excessive alcohol can increase burning, dryness, and odor. Propylene glycol can improve solubilization and hydration of the stratum corneum, but higher concentrations may increase tackiness or irritation.

A commercial formulation should optimize:

• Diclofenac solubility over the intended shelf-life range.
• Skin flux without excessive systemic exposure.
• Drying time after application.
• Residue on clothing and bedding.
• Odor and perceived medicinal character.
• Compatibility with the package closure and tube liner.

Polymer selection

Carbomer is a practical choice because it produces clear or translucent gels at low concentration and supports reproducible viscosity. The neutralization level is critical. Under-neutralization can produce a thin, poorly adhering gel. Over-neutralization can increase viscosity, alter drug ionization, and affect release.

Alternative polymers, including acrylate crosspolymers, hydroxyethylcellulose, poloxamers, and natural gums, create potential differentiation but also introduce risks:

• Cellulosic polymers may change clarity and microbial risk.
• Poloxamers may improve sensory properties but can alter temperature-dependent viscosity.
• Natural polymers may create batch variability and preservative challenges.
• Different carbomer grades can change yield stress, spreadability, and drug release.

Emollient and surfactant design

Cocoyl caprylocaprate and mineral oil help control glide and after-feel. Polyoxyl 20 cetostearyl ether supports emulsification and distribution of oil-soluble components. A lower-oil system may appeal to consumers who dislike residue, while an emollient-rich system may better serve users with dry or mature skin.

The commercial tradeoff is direct: a less greasy formulation can improve adherence to treatment, but a very volatile or alcohol-heavy gel can reduce tolerability.

What formulation patents protect topical diclofenac products?

Topical diclofenac has been commercialized for decades, and many basic composition concepts are likely to be expired or difficult to enforce in the United States. Commercial risk is more likely to arise from later-filed claims covering specific excipient ratios, manufacturing processes, delivery systems, package configurations, or methods of use.

A freedom-to-operate review should separate four patent categories:

Patent category	Relevant claim scope	Risk to an Aleve-like product
Composition patents	Diclofenac, solvent, polymer, surfactant, and pH ranges	High if claims cover narrow excipient ratios
Method-of-use patents	Treatment of osteoarthritis or specific joints	Moderate, especially for labeled indications
Manufacturing patents	Mixing order, neutralization, deaeration, or particle control	Moderate; often avoidable through process redesign
Device and packaging patents	Pumps, metered dispensers, applicators, and tubes	Moderate to high for differentiated packaging

The Orange Book is relevant only if the marketed product is tied to an FDA-approved application with listed patents or exclusivity. OTC monograph products and nonprescription products approved through different regulatory pathways may not present the same Orange Book profile as a conventional prescription NDA. The applicable FDA application, labeling record, and current Orange Book entry must be reviewed before relying on an absence of listed patents.[3,4]

When does Aleve Arthritis Pain Gel lose exclusivity?

Aleve Arthritis Pain Gel does not have a single exclusivity date that can be inferred from the brand name. The commercial protection profile depends on the regulatory pathway, application type, listed patents, trade dress, trademark rights, and any formulation or packaging patents.

For a generic or private-label competitor, the key dates are:

Protection type	Relevance
FDA marketing exclusivity	May delay certain abbreviated or competing approvals
Listed formulation patents	May create a patent certification or litigation issue
Method-of-use patents	May require labeling carve-outs
Trademark rights	Protect the Aleve name and brand presentation, not the active ingredient
Trade dress	May protect distinctive packaging elements
Regulatory exclusivity outside the U.S.	Varies by Canada, Europe, Australia, and other markets

Basic diclofenac topical products should be treated as a mature competitive category. The commercial barrier is more likely to be formulation development, regulatory documentation, channel access, and brand marketing than a broad, durable monopoly over diclofenac gel.

What FDA regulatory status applies to Aleve Arthritis Pain Gel?

FDA status depends on the specific product record. Diclofenac sodium topical gel products may be marketed under an approved application or under an applicable OTC pathway, while the Aleve brand itself is a trademark and does not establish the regulatory route.

A competing product must address:

• Active ingredient identity and concentration.
• Conditions of use and arthritis indications.
• Label warnings for NSAID risks.
• Manufacturing under current good manufacturing practice.
• Drug listing and establishment registration.
• Stability and container-closure compatibility.
• Microbial quality and preservative effectiveness.
• Product-specific bioequivalence or comparative performance expectations.
• Advertising and labeling consistency with the approved or permitted claims.

The label must also address external-use limitations, handwashing, eye contact, damaged skin, use with other NSAIDs, and cardiovascular and gastrointestinal risks where required by the applicable FDA labeling.[1,3]

What commercial opportunities exist for excipient-led differentiation?

Fragrance-free and sensitive-skin formulations

A lower-odor, lower-alcohol formulation could target older consumers, users with eczema-prone skin, and patients who discontinue topical products because of burning or dryness. Benzyl alcohol and high volatile-solvent content deserve particular review for these segments.

Potential positioning includes:

• Fragrance-free.
• Low-odor.
• Sensitive-skin tested, where substantiated.
• Lower-residue.
• Non-greasy.
• Fast-drying.

These claims require substantiation and cannot imply superior clinical efficacy without supporting evidence.

Improved delivery systems

A controlled-release gel, emulgel, foam, roll-on, or metered pump could improve convenience. A pump can reduce hand contact and control dose, but it increases packaging cost and may create device or combination-product complexity. A roll-on can support precise application to knees, hands, and elbows but may have limited appeal for larger joints.

Senior-friendly packaging

Arthritis patients may have impaired grip strength. Opportunities include:

• Larger, low-force caps.
• Flip-top closures.
• Pump dispensers.
• Tactile opening indicators.
• Clear dose markings.
• Tubes that remain stable when inverted.

Packaging patents and trade dress rights should be screened before launch.

Regional and channel-specific products

The same core gel can support several commercial formats:

Channel	Product opportunity
Mass retail	Standard tube with price-focused formulation
Pharmacy	Pharmacist-recommended sensitive-skin or low-odor version
E-commerce	Multipacks, pump formats, and subscription replenishment
Long-term care	Larger tubes, dose-control packaging, and lower handling burden
International markets	Country-specific diclofenac salt, strength, labeling, and excipient adaptation

Country-level regulatory differences are material. Canada, the European Union, the United Kingdom, and Australia may use different diclofenac salts, strengths, indications, and nonprescription classifications. A U.S. formulation cannot be assumed to qualify for direct international registration.

Which companies are challenging the Aleve Arthritis Pain Gel market?

The principal competitive groups are:

1. Brand owners selling topical diclofenac products, including Voltaren.
2. Generic manufacturers selling diclofenac sodium topical gel.
3. Private-label retailers.
4. Contract development and manufacturing organizations with topical semisolid platforms.
5. Alternative topical analgesic brands using menthol, lidocaine, capsaicin, salicylates, or counterirritants.

Generic competition is strongest where the product uses a standard 1% diclofenac gel, conventional tube packaging, and familiar excipients. Brand differentiation is more defensible when it combines a distinct sensory profile, better package usability, documented tolerability, and strong retail placement.

How strong is the patent estate for a new Aleve-like gel?

The patent estate for a conventional diclofenac sodium gel is likely weaker than the commercial brand position. A basic copy may avoid meaningful patent exposure if it uses an independently developed excipient system and does not copy protected packaging or labeling claims. Stronger protection is possible for:

• Narrow solvent and polymer ratios.
• Enhanced skin deposition.
• Reduced systemic exposure.
• Specific particle-size distributions.
• Novel emulgel structures.
• Metered-dose delivery.
• Combination therapy.
• Manufacturing controls that improve content uniformity.

A patent filing should focus on measurable technical advantages rather than routine excipient substitution. Useful claim-support data includes Franz-cell permeation, skin deposition, in vitro release, viscosity, tack, drying time, irritation scores, preservative challenge testing, and stability under accelerated conditions.

What generic launch scenarios exist?

Scenario 1: Standard generic tube

This is the lowest-cost entry strategy. It competes mainly on price and pharmacy or retail availability. The principal risks are limited differentiation and rapid price erosion.

Scenario 2: Private-label retail product

A retailer-branded product can capture margin through exclusive packaging and shelf placement. The formulation should remain close to the reference product to reduce development and regulatory risk.

Scenario 3: Premium low-irritation gel

A premium product can use a lower-odor solvent system, improved emollient balance, or a less tacky polymer network. It requires consumer testing and disciplined claims substantiation.

Scenario 4: Device-enabled product

A pump or roll-on can reduce handling and improve dose consistency. This strategy has higher packaging development costs and may create additional regulatory and patent obligations.

Scenario 5: International line extension

A manufacturer can adapt the platform for different diclofenac salts, concentrations, and regulatory categories. The opportunity is larger, but country-specific clinical, labeling, and excipient requirements increase execution risk.

Key Takeaways

• Aleve Arthritis Pain Gel is a topical diclofenac product whose commercial performance depends heavily on vehicle design.
• The main excipient functions are solubilization, penetration support, gel formation, pH control, emollience, emulsification, preservation, and sensory modification.
• Carbomer, propylene glycol, alcohol, diethylamine, surfactants, and emollients should be optimized as an integrated system.
• A basic diclofenac gel is likely to face mature generic competition and limited broad composition-patent protection.
• The most credible differentiation opportunities are low irritation, low odor, reduced residue, senior-friendly packaging, metered dosing, and regional adaptation.
• Orange Book and Paragraph IV analysis requires confirmation of the specific FDA application and current listed patents.
• A strong patent strategy should claim measurable delivery, tolerability, stability, packaging, or manufacturing improvements rather than routine excipient changes.
• The best near-term commercial opportunities are private-label products, premium sensitive-skin gels, and packaging-led line extensions.

FAQs

Is Aleve Arthritis Pain Gel the same as Voltaren Arthritis Pain Gel?

Both products are associated with topical diclofenac arthritis treatment, but the exact active ingredient presentation, excipient composition, manufacturer, labeling, and regulatory record should be confirmed for the applicable market.

Can a company launch a generic Aleve Arthritis Pain Gel without copying its excipients?

Yes. A competing product may use a different excipient system if it meets applicable regulatory requirements and does not infringe valid composition, process, packaging, trademark, or method-of-use claims.

Which excipient most affects diclofenac gel performance?

The solvent and cosolvent system often has the largest effect on drug solubility, skin permeation, drying, irritation, and sensory performance. Carbomer concentration and neutralization also materially affect residence time and release.

Is a diclofenac gel patent likely to block a private-label product?

A blocking risk is more likely to involve narrow formulation, manufacturing, packaging, or method-of-use claims than broad ownership of diclofenac gel technology. A product-specific patent and litigation search remains essential before launch.

What is the highest-value formulation improvement for an OTC arthritis gel?

A lower-irritation, low-odor formulation with fast drying, low residue, and senior-friendly packaging offers the clearest route to premium positioning, provided the product maintains acceptable diclofenac release and skin delivery.

References

1. U.S. Food and Drug Administration. (n.d.). Aleve Arthritis Pain Gel drug facts and labeling. DailyMed.

2. National Library of Medicine. (n.d.). Diclofenac sodium topical gel, 1%: Inactive ingredient and product labeling records. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Nonprescription drug products and OTC monograph regulatory resources. FDA.